Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ACONW ACLARION INC C/WTS (TO PUR COM)
0.170+0.020+13.33%
Close
01/27 16:00 ET
High
0.170
Open
0.150
Turnover
277.00
Low
0.116
Pre Close
0.150
Volume
2.09K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor
Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Aclarion’s Key Opinion Leader Program Adds Fifth Surgeon Advisor With Addition of Eric Potts, MD
Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy. Broomfield, CO, Dec. 21, 2022 (GL
Aclarion Adds to Growing Key Opinion Leader Program With Juan Uribe M.D. as a Surgeon Advisor
Dr. Uribe is the fourth national KOL to join the Aclarion team this year. Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer communi
Aclarion Announces Participation at the NASS 37th Annual Meeting
Nociscan utilized within unprecedented NIH HEAL Initiative featured at NASS 2022NociscanTM is the first evidence-supported SaaS platform to objectively analyze intradiscal painNociscan bridges major d
John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Aclarion Key Opinion Leader program supports focused strategy of building strong clinical evidence and payer community advocacy to drive adoption of NociscanTM solutionBROOMFIELD, CO / ACCESSWIRE / Oc
Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain
NIH funded Biomarkers for Evaluating Spine Treatments (BEST) Trial launching this quarterBEST to study the role of biomarkers in optimizing the treatment of chronic low back painNociscanTM to be comme
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
Initial findings from the EVAL study are expected to be released in Q4 2022Study initiated to assess impact of Nociscan on the cost of care for chronic low back pain (CLBP) patientsPromising initial c
Aclarion, Inc. Announces Closing of $9.4 Million Initial Public Offering
SAN MATEO, CA / ACCESSWIRE / April 26, 2022 / Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON) (NASDAQ:ACONW), a healthcare technology company that leverages Magnetic Resonance Spectroscopy
No More
Company Overview
More
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.
CEO： Mr. Brent Ness
Market： NASDAQ
Listing Date： 04/22/2022
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet